Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market

Democratic U.S. Senate aides will meet with Novo Nordisk executives on Tuesday to discuss fallout from its decision to stop selling one of its long-acting insulins in the country, two sources familiar with the meeting told Reuters.